The med-tech sector experienced some relief in the first quarter of 2024 (1Q24) as total financings climbed to $6.38 billion, eclipsing the value of any quarter in 2023. For perspective, the final quarter of 2023 recorded $3.32 billion, and 1Q23 raised $4.69 billion, with an average of $4.42 billion in financings per quarter in 2023.
Grey Wolf Therapeutics Ltd. added $50 million to its series B, bringing the total for the round to $99 million and providing funding to expand the scope of an ongoing phase I/II trial of its lead antigen modulation program.
Prologue Medicines Inc. has launched to develop therapeutics created from the viral proteome, which are proteins produced across all viruses. It’s a newer twist on harnessing the power of the proteins that regulate biology. The company was founded on the premise of peering beyond the human proteome to see if there were viral proteins that could become therapeutics, Theonie Anastassiadis, Prologue’s founding president, told BioWorld.
Sixpeaks Bio AG has emerged from stealth with $30 million in series A financing and a pipeline of therapies for healthy weight loss, including a dual-specific antibody targeting activin type IIA and B receptors for preservation of skeletal muscle mass.
Altrubio Inc. secured up to $225 million in an oversubscribed series B financing round, led by BVF Partners LP. The full amount is dependent on Altrubio meeting certain undisclosed milestones. New investors RA Capital Management, Cormorant Asset Management and Soleus Capital, and existing investors Amoon Fund and Blackstone Multi-Asset Investing, as well as other new and existing investors, also participated in the financing round.
RSS
